Mutations in PIGA cause a CD52‐/GPI‐anchor‐deficient phenotype complicating alemtuzumab treatment in T‐cell prolymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Haematology"
DOI: 10.1111/ejh.13511
Abstract: Infusional alemtuzumab followed by consolidating allogeneic hematopoietic stem cell transplantation in eligible patients is considered a standard of care in T‐cell prolymphocytic leukemia (T‐PLL). Antibody selection against CD52 has been associated with the development of… read more here.
Keywords: cd52; cell prolymphocytic; mutations piga; prolymphocytic leukemia ... See more keywords